HONG KONG, Jan. 27, 2026 — Fangzhou Inc. (“Fangzhou” or the “Company”) (HKEX: 06086), a leading provider of AI-driven Internet healthcare solutions, has successfully concluded a HK$150 million share placement, fortifying its balance sheet to expedite investment in artificial intelligence and platform upgrades.
The shares were priced at HK$3.32 per share, and the placed shares represent approximately 3.26% of the Company’s enlarged issued share capital after the completion of the subscription.
Fangzhou intends to allocate around 90% of the net proceeds after deducting related costs and expenses to accelerate the development of the Company’s AI-driven chronic disease management platform. This includes model development and optimization, expansion of infrastructure and computational resources, recruitment of talent across AI and clinical specialties, data collection and annotation, and knowledge base development, as well as the roll-out and marketing of AI-enhanced services to target underserved patient and physician populations.
The fundraising occurs amidst a resurgence of momentum in medical AI at the beginning of the year, as global and domestic technology players speed up the development of LLMs focused on healthcare. Fangzhou announced the completion of a major upgrade of its “AI + H2H (Hospital-to-Home)” ecosystem in 2025, integrating AI throughout the entire chronic disease management value chain to support continuous patient care while enhancing the efficiency of medical resource allocation.
With an early-mover advantage in AI-enabled chronic care, Fangzhou has attracted growing attention from institutional investors, including global investment banks, as China’s healthcare sector endeavors to explore models similar to OpenEvidence in the U.S., market observers noted.
The fundraising follows Fangzhou’s recent positive profit alert, in which the Company announced that based on a preliminary review of the Group’s unaudited consolidated management accounts, 2025 revenue would be in the range of RMB 3.5 billion to RMB 3.55 billion, showing an approximate 30% year-on-year growth, with a net profit of RMB 7 million to RMB 10 million, marking its first full year of profit after achieving positive adjusted net profit in 2024.
Looking ahead, Fangzhou will continue to utilize technology and AI to enhance chronic disease management and drive sustainable growth, while supporting the goals of China’s “Healthy China 2030” initiative.
About Fangzhou Inc.
Fangzhou Inc. (HKEX: 06086) is China’s leading online chronic disease management platform, serving 52.8 million registered users and 229,000 physicians (as of June 30, 2025). The Company specializes in providing tailored medical care and AI-enabled precision medicine solutions. For more information, visit .
Media Contact
For further inquiries or interviews, please reach out to:
Xingwei Zhao Associate Director of Public Relations Email: pr@jianke.com
Disclaimer: This press release contains forward-looking statements. Actual results may differ materially from those anticipated due to various factors. Readers are cautioned not to place undue reliance on these statements.
